Pharmaceuticals, Biotechnology and Life Sciences
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)
Interim efficacy and safety evaluation of the CALM Stud…
— FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration —
— Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —
CRANBURY, N.J.–(BUSINESS WIRE)–$RCKT #GeneTherapy–Rocket Pharmaceuticals, …
Partnership improves access to genetic counseling services when suspected hereditary cancer gene variant is identified through Foundation Medicine’s tumor testing
CAMBRIDGE, Mass. & ST. PETERSBURG, Fla.–(BUSINESS WIRE)–Foundation Medicine, Inc. and …
Gvoke® net sales of $20.2 million for full-year 2020
Continued Gvoke prescription growth – over 350% in 2020
Strong cash position of $133.8 million
Conference call and webcast today at 8:30 a.m. ET
CHICAGO–(BUSINESS WIRE)–#T1D–Xeris Pharmaceuti…
– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021-
— Omidubicel commercial p…
Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biotechnolog…
Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors
Maverick’s lead candidate TAK-186 (f…
Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors
Maverick’s lead candidate TAK-186 (f…
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)
Interim efficacy and safety evaluation of the CALM Stud…
— FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration —
— Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —
CRANBURY, N.J.–(BUSINESS WIRE)–$RCKT #GeneTherapy–Rocket Pharmaceuticals, …